Debt is smaller than equity and it can meet short-term obligations.
Metrics · D/E ~68% · Current Ratio 1.03
💲Is the price expensive now?
Not cheap (fair to slightly pricey)
Because it is a good, popular company, those expectations are already priced in.
Metrics · P/E 29.4 · P/B 7.5
💡Blue-chip healthcare (pharma + MedTech), a 64-yr Dividend King. Solid margins (27% op, 26% ROE), low debt; talc suits and Stelara's patent cliff are key risks.
Compiled from public financial data. Not a recommendation to buy or sell any security. · Source: TradingView (margins, debt, liquidity, P/B are TTM), as of 2026-06-26
Business Summary · Key Value Metrics
A global healthcare company built on two wings — pharmaceuticals (Innovative Medicine) and medical devices (MedTech). Having spun off its consumer arm Kenvue, it now focuses on drugs and devices. TTM revenue is $96.4B with a 26.9% operating margin. 64 consecutive years of dividend increases.
Johnson & Johnson is a global healthcare brand of more than 130 years, with a dual portfolio of pharmaceuticals (Innovative Medicine) and medical devices (MedTech). Profitability is high — $96.4B in revenue (TTM), a 26.9% operating margin, and a 68% gross margin — while FDA regulation and accumulated clinical data form entry barriers. It is a Dividend King with 64 straight years of increases (source: company IR · TradingView).
Brand power
A 130-year-plus global healthcare brand with top-tier trust and recognition.
Dual portfolio
Pharma and MedTech wings spread cyclical and patent risk.
Scale and switching costs
$96B in revenue, with hospital and device stickiness making switching costs high.
Regulatory barriers
FDA regulation and accumulated clinical data block new entrants.
10-Year Financial Trends
Revenue growth is modest at roughly +3% annualized over nine years, but the benefits of focusing on pharma and devices after the Kenvue spin-off are becoming visible. FY2025 revenue was $94.2B. Diluted EPS has swung sharply on one-off items — a 2017 tax charge ($0.48) and a 2024 talc provision ($5.79) — and spiked temporarily to $13.72 in 2023. As talc settlements progress, EPS is expected to normalize (source: SEC EDGAR 10-K · company IR).
9-Year CAGR: Revenue +3.3% · Operating Income Limited data · Net Income +5.5% · EPS +7.1%
Sources: SEC EDGAR 10-K · stockanalysis · company IR. GAAP basis; EPS is diluted. Revenue and EPS are SEC-reported (non-consecutive years; 2015 and 2020 not included); P/E and ROE cover the last 5 years (stockanalysis). The 10-year operating-income series is omitted due to data limits.
Mega-Cap Value Metric Comparison
JNJ's combined pharma-and-device portfolio makes it highly stable, but at a 29x P/E it trades at a premium to Merck (~13x) and AbbVie (~21x). Its 26.9% operating margin is among the best in the peer group (source: TradingView · company filings).
Metric
★ JNJ
MRK
ABBV
P/E (TTM)
29.4
~13
~21
Operating Margin
26.9%
~28%
~26%
Dividend Yield
2.10%
~3.6%
~3.8%
P/E and operating margin = TTM · sources: TradingView · company filings, 2026-06-26.
Key Risk Factors (from 10-K)
●
Patent cliff— Intensifying biosimilar competition for Stelara ($10B+ in sales) threatens to erode revenue.Source: Company 10-K
●
Talc litigation— Uncertainty over the final settlement cost of talc-related litigation is a swing factor for when EPS normalizes.Source: Courts · company IR
●
Drug-pricing regulation (IRA)— U.S. drug-price negotiation pressure could squeeze pharmaceutical profitability.Source: Regulators
✦ ValueCrab Dashboard PreviewJNJ $254.66 +3.99% · as of 2026-06-26
Q. What are Johnson & Johnson's (JNJ) key value-investing metrics?P/E (TTM) 29.4, ROE 26.4%, operating margin 26.9%, net margin 21.8%, dividend yield 2.10%, and 64 consecutive years of dividend increases (sources: TradingView · company IR, as of 2026-06-26).
Q. How is JNJ as a dividend stock?As a Dividend King with 64 straight years of increases, its dividend stability is very high. Strong free cash flow funds both the dividend and R&D. (This is informational, not a buy or sell recommendation.)
Q. Why is EPS so uneven?One-off items — a 2017 tax charge and a 2024 talc-litigation provision — drive large swings in GAAP EPS. As the talc settlement progresses, EPS is expected to normalize.